Bloomberg: Athenahealth has five potential bidders

Amy Baxter | | Health Exec | Policy & Regulations

Athenahealth, a network-enabled services company for hospitals and ambulatory clients, has bids from at least five entities, according to a report from Bloomberg. The bidders include Bain Capital, Hellman and Friedman, Clayton, Dubiliar & Rice and TPG.

Elliott Management Corp., which currently owns 9 percent of Athenahealth, is also reportedly considering a bid, according to Bloomberg.

The potential sale of Athenahealth comes after its CEO Jonathan Bush announced he was leaving the company in June after admitting to domestic violence allegations against his former wife.

Final bids are due by the end of the month for the company, though Elliott previously said in May it was prepared to make an offer for $160 per share—above the reported new bids of $135 per share. That previous deal was rumored to be worth around $7 billion.

See the full story below:

Athenahealth Has Bidder Interest Over $135 Per Share

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.